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Regulatory pathways involving non-coding RNAs (ncRNAs), such as microRNAs
(miRNAs) and long non-coding RNAs (lncRNA), have gained great relevance due to
their role in the control of gene expression modulation. Using RNA sequencing of KSHV
Bac36 transfected mouse endothelial cells (mECK36) and tumors, we have analyzed the
host and viral transcriptome to uncover the role lncRNA-miRNA-mRNA driven networks in
KSHV tumorigenesis. The integration of the differentially expressed ncRNAs, with an
exhaustive computational analysis of their experimentally supported targets, led us to
dissect complex networks integrated by the cancer-related lncRNAs Malat1, Neat1, H19,
Meg3, and their associated miRNA-target pairs. These networks would modulate
pathways related to KSHV pathogenesis, such as viral carcinogenesis, p53 signaling,
RNA surveillance, and cell cycle control. Finally, the ncRNA-mRNA analysis allowed us to
develop signatures that can be used to an appropriate identification of druggable gene or
networks defining relevant AIDS-KS therapeutic targets.
Keywords: long non-coding RNAs, microRNAs, KSHV, network pathways, druggable targetsINTRODUCTION
Non-codingRNAs (ncRNAs) areRNA transcripts that donot encode proteins and based on the length can
be divided into two classes: small ncRNAs (sncRNAs), with transcripts shorter than 200 nucleotides, and
long ncRNAs (lncRNAs), with transcripts longer than 200 nucleotides (1). Regulatory pathways involving
ncRNAs, suchasmicroRNAs (miRNAs), belonging to the class of sncRNA, and lncRNAshavegainedgreat
relevance due to their role in the control of gene (mRNA) expression. Different modes of interactions
between lncRNAs andmiRNAs have been reported: miRNA decay of lncRNAs, lncRNAs competing with
mRNAs to bind to miRNAs, lncRNAs competing with miRNAs to bind to mRNA, and lncRNAs being
shortened tomiRNAs (2, 3).All these interactions regulate the expression levels ofmRNAsand in turnaffect
core protein signals, resulting in changes in the physiological functions of cells.June 2021 | Volume 11 | Article 6876291
Naipauer et al. Non-Coding RNAs in KSHV TumorigenesisKaposi’s sarcoma (KS) is an AIDS-associated malignancy
caused by the KS herpesvirus (KSHV). Despite the reduction
of its incidence since the implementation of anti-retroviral
therapy (ART), KS continues to be a global, difficult-to-treat
health problem, in particular for ART-resistant forms (4, 5). KS
is characterized by the proliferation of KSHV-infected spindle
cells and profuse angiogenesis (6).
The life cycle of KSHV has two well-defined phases: latent
and lytic. In the latent phase, the virus expresses a few genes
involved in viral persistence and host immune evasion. During
the lytic phase, which is triggered by environmental and/or
physiological stimuli, the viral genome replicates and new
virions are formed (7). At this stage, KSHV is particularly
effective at exploiting host gene expression for its own benefit.
In this sense, the coevolution of the virus and its host has
developed an intricate association between the virus genome,
with its coding genes and non-coding genes, and the host RNA
biosynthesis machinery (8). To the point that KSHV can seize
control of RNA surveillance pathways, such as DNA damage
response (DDR), pre-mRNA control machinery and the
Nonsense-mediated mRNA decay (NMD), to fine-tuning the
global gene expression environment throughout both phases of
infection (7, 9, 10).
A recent study of KSHV-infected TIVE cells using wild-type
and miRNA-deleted KSHV in conjunction with microarray
technology to profile lncRNA expression found that KSHV can
deregulate hundreds of host lncRNAs. These data established that
KSHV de-regulates lncRNA in a miRNA-dependent fashion (11).
Using deep RNA sequencing of KSHV Bac36 transfected
mouse endothelial cells (mECK36) and tumors (12), we have
previously analyzed the host and viral transcriptome to
characterize mechanisms of KSHV-dependent and -independent
sarcomagenesis, as well as the contribution of host mutations (13).
We now decided to study in this model, in a genome-wide
fashion, the ncRNAs landscape to better understand the
relationship between mRNAs, lncRNAs, and miRNAs in
shaping KSHV tumorigenesis mechanisms.
This study allowed us to identify the most relevant host lncRNAs
involved in KSHV tumorigenesis through the mouse KS-model
(Malat1, Neat1, H19, and Meg3). In addition to having common
target genes, pathway analysis showed that the four lncRNAs also
share common related processes, mainly associated with cancer and
viral infections, which would contribute with a network of gene-
pathways closely associated with KSHV oncogenesis. We also
showed evidence of the most frequent viral lncRNAs transcripts
expressed in our model.
On the other hand, small RNA-sequencing and miRNA
analysis revealed a high proportion of upregulated host
miRNAs dependent of KSHV infection, indicating that the
presence of KSHV has a significant impact on the metabolism
of host miRNAs, whose target genes are mainly associated to
angiogenesis, ECM, spliceosome, p53 signaling, viral infections,
and cell cycle control. Similarly, functional analysis of KSHV
miRNA targets showed enrichment in processes, such as cell
cycle, spliceosome, RNA transport, microRNA regulation of
DDR, and p53 signaling, suggesting that viral miRNAs might
mimic cellular miRNAs.Frontiers in Oncology | www.frontiersin.org 2The integrative analysis of viral and host non-coding and
coding RNAs and the related processes showed a landscape of
the potential relationships of lncRNA-miRNA-mRNA in a
KSHV setting. This network highlights that the upregulated
genes are involved in processes previously related to KSHV
tumorigenesis while downregulated genes are associated with
host cell cycle checkpoints and RNA surveillance pathways: G1 to
S cycle control, p53 activity regulation, MicroRNA regulation of
DDR, Spliceosome, RNA transport, E2F transcription factor
network. Finally, the ncRNA-mRNA analysis in the animal
model presented here allowed us to develop signatures that can
be used to identify druggable gene or networks defining relevant
AIDS-KS therapeutic targets.METHODS
RNA-Sequencing Analysis
RNA-sequencing raw data used in the present study were
obtained as previously described (13). Data are available at
https://www.ncbi.nlm.nih.gov/geo/, GSE144101. Briefly, RNA
was isolated and purified using the RNeasy mini kit (Qiagen).
RNA concentration and integrity were measured on an Agilent
2100 Bioanalyzer (Agilent Technologies). Only RNA samples
with RNA integrity values (RIN) over 8.0 were considered
for subsequent analysis. mRNA from cell lines and tumor
samples were processed for directional mRNA-sequencing
library construction using the Preparation Kit according to
the manufacturer’s protocol. Paired-end sequencing using an
Illumina NextSeq500 platform was used, all samples were
processed in the same sequencing run of Illumina NextSeq 500
system and analyzed together with the aim to avoid the batches
effect. The short sequenced reads were mapped to the mouse
reference genome (GRCm38.82) by the splice junction aligner
TopHat V2.1.0. Several R/Bioconductor packages to accurately
calculate the gene expression abundance at the whole-genome
level using the aligned records (BAM files) were used. The
number of reads mapped to each gene based on the Mus
musculus genome assembly GRCm38 (mm10) were counted,
reported and annotated using the featureCounts package. To
identify DE genes between cell lines and tumor samples, we
utilized the DESeq2 package in R/Bioconductor. DESeq2
performs an internal normalization where geometric mean is
calculated for each gene across all samples. The counts for a gene
in each sample are then divided by this mean. For ncRNA
annotation we employed biomaRt package in R/Bioconductor.
We considered the Ensemble transcript ID, the Ensembl gene ID,
the Entrezgene ID, the HGNC symbol, the Refseq ncRNA ID and
the ReqSeq ncRNA predicted ID. After Deseq2 analysis on all
ncRNAs, we filtered out those belonged to the following classes:
small nuclear RNA (snRNA), small nucleolar RNA (snRNA),
predicted and or pseudogenes, and RIKEN genes; and kept the
classes lncRNA and miRNA.
Cell Culture and Tumors
Cells and tumors employed in the present study were the same as
previously described (13). mECK36, KSHV (+) cells, wereJune 2021 | Volume 11 | Article 687629
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generated (12). Briefly, mECs were obtained from Balb/C An
Ncr-nu mice (NCI, Bethesda, MD) bone marrow. Mice femurs
were flushed twice with PBS, and the eluates were incubated in
DMEM media plus 30% FBS (Gemini Bioproducts, Calabasas,
CA), 0.2 mg/ml Endothelial Growth Factor (EGF) (Sigma,
Saint Louis, MO), 0.2 mg/ml Endothelial Cell Growth Factor
Supplement (ECGS) (Sigma, Saint Louis, Missouri), 1.2 mg/1
heparin (Sigma, Saint Louis, MO), insulin transferrin selenium
(Invitrogen,Carlsbad, CA), 1% penicillin-streptomycin (Invitrogen,
Carlsbad, CA), and BME vitamin (VWR Scientific, Rochester, NY).
Cells transfected with KSHVBac36, the vector containing the insert
with the genome of KSHV in Bacterial Artificial Chromosome
(KSHVBac36) was obtained as described previously, were selected
with Hyg-B (12). KSHV (+) tumors were obtained as previously
shown, 1x106 KSHV (+) cells were injected subcutaneously into
the flanks of nude mice and KSHV (+) tumors formed 5 weeks
after injection. KSHV (−) cells were used from frozen populations
of KSHV null mECK36 previously obtained (12). KSHV (−) tumor
cells were obtained from frozen stocks previously generated by
explanted mECK36 tumor cells that have lost the Bac36-KSHV
episome (12). These KSHV-negative cells were obtained from
frozen stocks previously generated (14). KSHV (−) tumors were
obtained as previously shown (12), 1x106 KSHV (−) tumor cells
were injected subcutaneously into the flanks of nude mice and
KSHV (−) tumors formed 3 weeks after injection.
KSHV lncRNA Analysis
Cells and tumors employed in the present study were the same as
previously described (13). For lncRNA analysis we included the
generated BAM files from eight samples (2 KSHV (+) cells and
six KSHV (+) tumors). Based on the KSHV 2.0 reference genome
and genome coordinates, we annotated 12 lncRNAs. For
measuring gene expression, we applied featureCounts function
of the RSubread package in R/Bioconductor. For DEG analysis,
we employed DESeq2 package in R/Biocoductor.
Small RNA Sequencing and
miRNA Analysis
RNAwas isolated and purified using RNeasy PlusMini Kit (Qiagen,
#74134) following the RNeasy MinElute Cleanup Kit (Qiagen,
#74204) to separate purification of small RNA (containing
miRNA) and larger RNA, the small RNA eluate is enriched in
various RNAs of <200 nucleotides. A total of 15 small RNA ranged
from cell lines to primary mouse tumors in the presence or absence
of KSHV, were processed and sequenced on a HiSeq 2500 System
(Illumina, USA). Each sample yielded, on average, 17 million reads,
with the exception of one sample (DS016) that was excluded from
the analysis for presenting a low number of total reads. Nearly all
bases showed scores > Q30 for all reads. Trimmomatic was used to
remove adapters and quality control was checked with FastQC.
Reads weremapped to a combinedmouse and KSHV genome using
the bowtie aligner (ver. 1.1.1). To identify novel and known
miRNAs we used miRDeep2 package (ver. 2.0.0.7). A hybrid
genome of the mouse and the KSHV virus was used for all
analyzes in order not to bias the mapping results for or againstFrontiers in Oncology | www.frontiersin.org 3any of the two separate genomes. The source for all knownmiRNAs
was miRBase (ver. 21). KSHV transcriptome was analyzed using
previous resources and KSHV 2.0 reference genome. To identify DE
miRNAs across the different comparisons, we utilized the DESeq2
test based on the normalized number of counts mapped to each
miRNA. For data integration and visualization of DE transcripts we




To identify EVT genes regulated by the selected lncRNAs we
employed LncRNA2Targetv2.0 (http://123.59.132.21/
lncrna2target) and LncTarD (http://biocc.hrbmu.edu.cn/
LncTarD/) databases (15, 16). To identify the common targets
among the different lncRNAs we used Venn diagrams. To obtain
the experimentally supported targets of the DE host miRNAs
identified in this study, we employed DIANA TARBASE v8
(https://carolina.imis.athena-innovation.gr/diana_tools/). For
KSHV miRNAs targets we also used DIANA TARBASE v8
resource (17). In both cases, only those targets identified by
High-throughput methodologies were considered. To identify
relevant pairs of lncRNA-miRNA in our model, we used
DIANA-LncBase v3 (18), in which lncRNA/miRNA interactions
are defined by low-/high-throughput methodologies; for each of the
four lncRNAs we searched for their highly confident experimentally
supported viral and host miRNA targets. To identify drug-
associated genes or networks we used the drug gene interaction
database (DGIdb; https://www.dgidb.org/) and the miRNA
Pharmacogenomics Database (Pharmaco miR; http://www.
pharmaco-mir.org/) (19, 20). ClinicalTrials.gov database (https://
clinicaltrials.gov/) was consulted to search for all recruiting and
non-recruiting studies of KS patients.
Functional enrichment analyses were performed using the
ClueGo Cytoscape’s plug-in (http://www.cytoscape.org/) and the
Enrichr resource (https://maayanlab.cloud/Enrichr/) based on
the lists of EVT that were in turn deregulated transcripts across
the different comparisons of our model. For pathways terms and
annotation, we used those provided by KEGG and BioPlanet
(http://tripod.nih.gov/bioplanet/; https://www.genome.jp/kegg/
pathway.html). Significant pathways were based on the
Bonferroni Adjusted p value <0.05. To combine and integrate
expression data with the results of the functional analysis we used
the GOplot package. For the construction of the networks, we
used Sankey plots.
All statistical analyses and data visualization plots were done
with R/Bioconductor packages.RESULTS
Genome-Wide Analysis of Non-Coding
RNAs in a Cell and Animal Model of
Kaposi’s Sarcoma
To analyze the ncRNA expression profile in a cell and animal
model of Kaposi’s sarcoma, we performed deep RNA-seqJune 2021 | Volume 11 | Article 687629
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schematic representation of the model: tumors formed by KSHV
Bac36 transfected mouse endothelial cells, KSHV (+) cells, are all
episomally infected with KSHV Bac36, and when KSHV (+) cells
prior to form tumors lose the KSHV episome in vitro by
withdrawal of antibiotic selection, KSHV (−) cells, they
completely lose tumorigenicity (12, 13). In contrast to KSHV
(−) cells, cells explanted from KSHV (+) BAC36 tumors and
grown in the absence of antibiotic selection lose the KSHV
episome, KSHV (−) tumor cells, are tumorigenic and are able
to form KSHV (−) tumors (12–14).
Unsupervised clustering (Figure 1B) and Multidimensional
plot (Figure 1C) of the host ncRNAs shows how KSHV status
and tissue type cluster with each other. As was previously
reported based on mRNA proliles, in vitro and in vivo models
clustered separately (13).
To identify changes in host lncRNAs expression profile, we
analyzed the number of differentially expressed (DE; FC>1.5, p
value <0.05) lncRNAs in key biological comparisons that were
detected by RNA-sequencing analysis of: two KSHV (+) cells,
two KSHV (−) cells, six KSHV (+) tumors, two KSHV (−) tumor
cells and three KSHV (−) tumors (Supplementary Table 1). This
mouse model allows for unique experimental comparisons in the
same cell and KS-like mouse tumor types: 1) KSHV (−) cells
versus KSHV (+) cells can be used to study KSHV mediated
effects in vitro, 2) KSHV (−) tumors versus KSHV (+) tumors can
be used to dissect the role of ncRNAs in tumorigenesis by
comparing tumors driven by KSHV versus tumors driven byFrontiers in Oncology | www.frontiersin.org 4host mutations, 3) KSHV (+) cells grown in vitro and in tumors
can be used to study in vitro versus in vivo variations induced by
micro-environmental cues, and 4) KSHV (−) tumor cells versus
KSHV (−) tumors can be used to study in vitro versus in vivo
variations in the absence of KSHV (13). We first analyzed
lncRNAs expression in these comparisons and found that the
highest number of DE lncRNAs was observed in KSHV (+)
tumors in both comparisons versus KSHV (−) tumors and versus
KSHV (+) cells (Figure 1D and Supplementary Table 1).
Identification of Relevant lncRNAs in
KSHV (+) Tumors
We performed heat map representations of all or top-50 DE
lncRNAs -according to each comparison- for all the four
biological relevant comparisons mentioned previously
(Figure 2A). To select and further evaluate relevant KSHV-
associated lncRNAs we searched for the common up-modulated
lncRNAs in KSHV (+) tumors versus the different comparisons
(Figure 2B). Of the 10 lncRNAs up-modulated in KSHV (+) cells
compared to KSHV (−) cells, 3 lncRNAs (Malat1, Neat1 and
Kcnq1ot1) were also up modulated in the comparison of KSHV
(+) tumors versus KSHV (−) tumors (Figure 2B, top panel). In
addition, of the 40 up-modulated lncRNAs in KSHV (+) tumors
versus KSHV (+) cells, 18 were common to the 25 up-modulated
lncRNAs in the comparison between KSHV (+) tumors and
KSHV (−) tumors (Figure 2B, bottom panel). These 18 genes
included lncRNAs such as Malat1, H19, Meg3, Neat1, Dio3os,
Miat,Mirg, and Rian, but also the miRNA genesMir140,Mir142,A
B DC
FIGURE 1 | Genome-wide analysis of Non-coding RNAs in a cell and animal model of Kaposi’s Sarcoma. (A) Schematic representation of the mouse-KS cell and
tumor model. (B) Unsupervised clustering of the host ncRNA transcriptome. (C) Multidimensional scaling plot of the host ncRNAs showing the distance of each
sample from each other determined by their leading log Fold Change (FC). (D) Workflow analysis and number of DE lncRNAs in key biological comparisons that were
detected by RNA-sequencing analysis of: two KSHV (+) cells, two KSHV (−) cells, six KSHV (+) tumors, two KSHV (−) tumor cells and three KSHV (−) tumors.June 2021 | Volume 11 | Article 687629
Naipauer et al. Non-Coding RNAs in KSHV TumorigenesisMir27b, andMir378b, among others (Figure 2B). Eventually, the
analysis allowed us to select four lncRNAs with a very interesting
pattern of expression through the different biological relevant
comparisons (Malat1, Neat1, H19 andMeg3).Malat1 and Neat1
are upregulated in KSHV (+) cells and KSHV (+) tumors when
compare with their KSHV (−) counterparts, suggesting a KSHV-
dependent upregulation of these lncRNAs (Figure 2C). H19 and
Meg3 are upregulated during the transition in vitro to in vivo in
the presence of KSHV (KSHV (+) tumors versus KSHV (+)
cells), but in this same transition in the absence of KSHV these
lncRNAs are not upregulated (KSHV (−) tumors versus KSHV
(−) tumor cells). This pattern of expression indicates a KSHV-
dependent regulation of these lncRNAs during this transition
induced by environmental cues (Figure 2C).
Pathway Analysis of the lncRNAs, Reveals
KSHV Closely Related Bioprocesses
To contextualize the selected lncRNAs into functional processes,
we employed LncRNA2Target v2.0 and LncTarD databases (15,
16) as resources of lncRNA-target relationships. Since the four
selected lncRNAs have been studied more extensively in humans
than in mice we searched for their experimentally validated
targets (EVT) (Supplementary Table 2). Functional
enrichment analysis (KEGG) of the resulting lists of genes
revealed several related pathways common to the fourFrontiers in Oncology | www.frontiersin.org 5lncRNAs, mainly cancer-related pathways and bioprocesses
associated with viral diseases (Supplementary Figure 1 and
Supplementary Table 2). Interestingly, KSHV infection and
MicroRNAs in cancer were the common signature of the 4
lncRNAs (Supplementary Figure 1).
Next, we established a list of the total human target genes
contributed by the 4 lncRNAs and looked for their homologues
among the DE host genes previously obtained across the different
comparisons of our model (Figure 3A and Supplementary
Table 3). Figures 3B–D, shows the chord plots illustrating the
biological process terms and the target genes of the four lncRNAs
contributing to that enrichment arranged in order of their
expression level in the corresponding comparisons
(Supplementary Table 3). Processes such as Integrins in
Angiogenesis (with the genes Spp1, Vegfa, Fn1, Kdr, Igf1r),
Signaling by PDGF (Vegfa, Kdr, Cdkn1a, Igf1r), HIF-1 signaling
(Vegfa, Hif1A, Stat3, Il6, Cdkn1a, Pik3r1, Igf1r), MicroRNAs in
cancer (Dicer1, Zeb1, Zeb2, etc.) and KSHV infection (Fgf2, Hif1a,
Stat3, Il6, Pik3r1, Jak2, Rb1, Jun) were overrepresented by
upregulated target genes in KSHV (+) tumors compared with
KSHV (−) tumors. Apoptosis (Mdm2, Bax, Myc, Casp3) and p53
activity regulation (Mdm2, Bax, Casp3, Pcna) were instead
associated with downregulated genes in the KSHV-bearing
tumors (Figure 3B and Supplementary Table 3). Similar
findings were observed in the comparison KSHV (+) cellsA B
C
FIGURE 2 | Host lncRNAs expression. (A) Heat maps for fold change expression of host lncRNAs based on analysis of RNA sequencing data, all or the top 25
upregulated (red) and top 25 downregulated (blue) DE lncRNAs are shown in each comparison. (B) Venn diagrams showing upregulated host lncRNAs common in
KSHV (+) cells and tumors versus KSHV (−) cells and tumors (top), and upregulated host lncRNAs common in KSHV (+) tumors versus KSHV (+) cells and KSHV (+)
tumors versus KSHV (−) tumors (bottom). (C) Relative abundance of selected lncRNA RNAs across the different steps of the mouse-KS cell and tumor model. The
asterisk refers to the level of statistical significance, established at p value <0.01.June 2021 | Volume 11 | Article 687629
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particular contribution of upregulated target genes associated
with Extracellular Matrix Organization and Activation of Matrix
Metalloproteinases (MMP), represented by Mmp2, Mmp9,
Mmp13, and Mmp14 (Figure 3C and Supplementary
Table 3). Also, pathways of DNA integrity control and cell
cycle checkpoints, such as Tp53 network, MicroRNA regulation
of DDR and G1 to S cell cycle control were revealed in this
comparison, represented by the downregulated genes E2f1, Bax,
Dnmt1, Cdkn1a, Myc, or Mdm2. Interestingly, in the transition
in vitro to in vivo but in the absence of KSHV we found processes
related to the terms KSHV infection (Ccnd1, Ctnnb1, Map2k2,
Stat3, Pik3r1, Jun, Erbb2, Igf1r) and MicroRNAs in cancer
(Dicer1, Ccnd1, Ctnnb1, Sp1, etc.) associated with down-
modulated genes in KSHV (−) tumors (Figure 3D and
Supplementary Table 3), in contrast to that observed in the
KSHV-dependent transition (Figure 3C).
Taking together, the integrative in-silico analysis of the
lncRNAs-EVT and their associated pathways, with the host
transcriptome derived from our model, reveals that the
upregulation of Malat1, Neat1, H19, and Meg3 in KSHV (+)
tumors would contribute with a network of gene-pathways
closely related with KSHV oncogenesis.Frontiers in Oncology | www.frontiersin.org 6KSHV-Dependent In Vitro to In Vivo
Transition Is Defined by a Significant
Up-Regulation of Host miRNAs
LncRNAs have been demonstrated to regulate gene expression
by various mechanisms, including epigenetic modifications,
lncRNA-miRNA specific interactions, and lncRNAs as miRNA
precursors. Our previous approach showed clear relationship
among the four selected lncRNAs and miRNAs in cancer.
Therefore, we performed small-RNA sequencing on the
samples obtained from our model to identify host DE
miRNAs. Next, we conducted an integrated bioinformatics
workflow to elucidate relevant networks of lncRNA-miRNA-
mRNA during KSHV tumorigenesis.
Unsupervised analysis of 14 samples based on miRNAs
expression profiles shows how they cluster together in an
unsupervised way according to their predefined features
(Figure 4A). Interestingly, the samples cluster in the same
pattern as when the analysis was made for lncRNAs (Figure 1B)
and also for all host genes in our previous study (13). The distance
among groups is reflexed in the number of DE miRNAs
(Figure 4B and Supplementary Table 4). Remarkably, the
higher proportion of upregulated miRNAs was observed in
KSHV (+) tumors (95% of DE miRNAs) compared with KSHVA B
DC
FIGURE 3 | Pathway analysis of selected DE lncRNAs and their EVT genes. (A) Schematic representation of the EVT genes of Malat1, Neat1, H19 and Meg3 that
were correlated with gene expression in the RNA-sequencing analysis. (B–D) Chord plot illustrating the GO biological process terms and the target genes
contributing to that enrichment arranged in order of their expression level in KSHV (−) tumors versus KSHV (+) tumors (B), KSHV (+) cells versus KSHV (+) tumors
(C) and KSHV (−) tumor cells versus KSHV (−) tumors (D). The corresponding lncRNAs are indicated with color boxes besides each target gene.June 2021 | Volume 11 | Article 687629
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KSHV (−) tumors (90% of DE miRNAs) compared with KSHV
(−) tumor cells (Figure 4B and Supplementary Table 4). This
result is consistent with that previously described in which the
term MicroRNAs in cancer was associated with upregulated genes
in KSHV (+) tumors and down-regulated genes in KSHV (−)
tumors (Figures 2B, C). Such difference could be partly explained
by Dicer1, a master regulator of miRNA biosynthesis, which is in
turn linked to the lncRNA H19 (Figures 3B, D). We performed
heat map representations of all or top-50 DE microRNAs
-according to each comparison- for all the 4 biological relevant
comparisons mentioned previously (Figure 4C).Differentially Expressed miRNAs Regulate
Gene Targets Related to KSHV Affected
Biological Processes
Mature miRNAs regulate gene expression at the posttranscriptional
level via partial base-pairing with their target mRNAs. Such
interaction leads to mRNA degradation and/or translational
inhibition, causing the downregulation of proteins encoded by
the miRNA-targeted mRNAs, a biological phenomenon termed
RNA interference (RNAi) (21). In silico-based functional analysis ofFrontiers in Oncology | www.frontiersin.org 7miRNAs usually consists of miRNA target prediction and
functional enrichment analysis of miRNA targets.
To identify the experimentally supported targets from our
previous published work (13) for the DE miRNAs identified in
this study, we employed DIANA TARBASE v8 (17). Next, we
selected those targets whose expression antagonizes with that of
its miRNA in the corresponding comparison (Figure 5A and
Supplementary Table 5). As we mentioned before, most of DE
miRNAs in the KSHV (−) tumors versus KSHV (+) tumors were
upregulated in KSHV (+) tumors, thus their corresponding
targets were downregulated in the same group. Pathways
analysis of these downregulated genes indicated enrichment in:
P53 signaling pathway (Bax, Gorab, Ccng1, Rrrm2, etc.),
Spliceosome (Tra2a, Tra2b, Srsf10, Snrpb, Snrpb2, etc.), E2F
transcription factor (E2f6, E2f7, Rrm1, Rbl1, etc.) and Cell cycle
(Xpo1, Nedd1, Zwint, Psma1, Psma3, etc.), among others
(Figure 5B and Supplementary Table 5).
In the in vitro to in vivo transition, with a more proportional
distribution of DE miRNAs, upregulated and downregulated
target genes were consequently identified, which provided
greater enrichment of bioprocesses closely related to the
obtained with the lncRNA targets in the same comparison. As
can be seen in the chord plot of Figure 5C, upregulated targetA B
C
FIGURE 4 | Host miRNAs expression. (A) Multidimensional scaling plot of the host miRNAs showing the distance of each sample from each other determined by
their leading logFC. (B) Number of DE miRNAs in key biological comparisons that were detected by small RNA-sequencing analysis of: two KSHV (+) cells, two
KSHV (−) cells, six KSHV (+) tumors, two KSHV (−) tumor cells and three KSHV (−) tumors. (C) Heat maps for fold change expression of host miRNAs based on
analysis of small RNA sequencing data, only top 20 upregulated and top 20 downregulated DE host miRNAs are shown in each comparison.June 2021 | Volume 11 | Article 687629
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with processes such as Integrins in Angiogenesis (Col1a12,
Col4a1, Col6a2, Itgb3, etc.), ECM-receptor interaction (Itga4,
Itgb3, Itgb8, Sdc1, Col1a2, etc.), MAPK signaling pathway
(Rps6ka3, Cebpa, Map3k1, Map314, etc.), Platelet activation
signaling (Vav3, App, Fga, Col1a2, Tgfb3, etc.) and Signaling by
PDGF (Pdgfra, Col4a1, Col4a2, Col6a2, Camk4, Foxo1, etc.).
Meanwhile, in the lower half of the plot, the viral infections
related processesHPV (Tcf7, Fzd4, Itga4, Tcf7, Tnf, etc.) andHIV
(Xpo1, Npm1, Nup50, Nup153, Nup160, Nup205, etc.), and the
p53 signaling (Dusp5, Ddit4, Ccng1, etc.) are over-represented by
downregulated genes (Figure 5C and Supplementary Table 5).
Within the latter, it is worth highlighting the presence of
numerous genes related to the nuclear export machinery
(Ranbp1, Ran, Xpo1, Nup50, Nup153, Kpnb1, Ncbp1). Lastly, in
the in vitro to in vivo transition in the absence of KSHV, fewer
terms were significantly over-represented by the miRNAs target
genes. Among them highlights Tight junctions, linked to down-
regulated genes, and Arf6 signal transduction over-represented
by the up-regulated ones (Figure 5D and Supplementary
Table 5).
Collectively, these results indicate that the presence of KSHV
has a significant impact on the metabolism of host miRNAs,
which contribute to the regulation of host genes linked to
processes of angiogenesis, ECM, transcriptional metabolism,
viral infections and cell cycle control, mainly.Frontiers in Oncology | www.frontiersin.org 8KSHV miRNAs and lncRNAs Expression in
Mouse KSHV (+) Tumors
To study the relevance of KSHV miRNA expression in KSHV
tumorigenesis we used the small-RNA sequencing data of read
counts to analyze the relative expression between miRNAs in
KSHV (+) tumors (Figure 6A). The ten most frequent
microRNAs in KSHV (+) tumors were K12-4-3p, K12-3-5p,
K12-8-3p, K12-10a-3p, K12-2-5p, K12-7-3p, K12-4-5p, K12-1-
5p, K12-11-3p, K12-3-3p representing 97% of the counts
detected for viral microRNAs in KSHV (+) tumors
(Supplementary Table 6).
Following the same criteria used for host ncRNAs, we
searched for KSHV miRNA targets. To do this, we considered
the top 10 most frequent KSHV miRNAs (Figure 6A). We used
Tarbase V8 database (17), and obtained a list of 2168 human
experimentally supported gene targets (Supplementary Table 6).
Next, we looked for their homologues in mice, which were
downregulated in KSHV (+) tumors in comparisons 2 and 3
(Figure 1A). A total of 220 genes were obtained for which
functional enrichment was performed (Supplementary
Table 6). Interestingly, once again, processes closely related to
those previously found for host ncRNAs were obtained
(Figure 6B): Cell cycle (Ccne2, Cdkn1a, Hdac2, Mdm2, Pcna,
etc.); Spliceosome (Hnrnpc, Hnrnpk, Hnrnpu, Magohb, Prpf40a,
Sf3a1, Snrpb2, Srsf1, etc.); miRNA regulation of DDR (Casp3,
Ccne2, Ccng1, Cdkn1a, Mdm2, Tnfrsf10b); Viral carcinogenesisA B
D
C
FIGURE 5 | Pathway analysis of DE miRNAs and their experimentally validated target (EVT) genes. (A) Schematic representation of the miRNA–mRNA pairs with
significant (p < 0.05) antagonistic expression. (B–D) Chord plot illustrating the GO biological process terms and the target genes contributing to that enrichment
arranged in order of their expression level in KSHV (−) tumors versus KSHV (+) tumors (B), KSHV (+) cells versus KSHV (+) tumors; for a better visualization only a
fraction of the genes corresponding to the plot is shown. The full list is available in Supplementary Table 5 (C) and KSHV (−) tumor cells versus KSHV (−) tumors (D).June 2021 | Volume 11 | Article 687629
Naipauer et al. Non-Coding RNAs in KSHV Tumorigenesis(Casp3, Ccne2, Cdkn1, Gtf2h1, Hdac2, Hist1h4d, Kat2a, Mdm2,
etc.), p53 signaling (Casp3, Ccne2, Ccng1, Cdkn1a, Gtse1, Mdm2,
Sesn2, Tnfrsf10b, etc.) or RNA transport (Eif1ax, Eif2s1, Eif4a1,
Fxr1, Kpnb1, Magohb, Nup155, Nup43, Xpo1, Xpot).
Among other non-coding RNAs KSHV encodes a number of
lncRNAs (7). We inquired into the RNA-seq data and identified
seven out of twelve annotated lncRNAs, with detectable levels of
expression in KSHV (+) cells and tumors. As-ORF7, as-K5/K6, as-
ORF65/69, and ALT were the most abundant transcripts
(Supplementary Table 6). DEG analysis between KSHV (+) cells
and KSHV (+) tumors identified as-ORF7 and as-K5/6 upregulated
in the transition in vitro to in vivo (Supplementary Figure 2 and
Supplementary Table 6), further indicating a possible role of these
KSHV lncRNAs in tumorigenesis.
Identification of a lncRNA-miRNA-mRNA
Interaction Network Involved With
KSHV Tumorigenesis
LncRNAs can also serve as regulatory elements of the RNAi
pathway (22). Indeed, host lncRNA transcripts are involved notFrontiers in Oncology | www.frontiersin.org 9only with the maturation of miRNA transcripts but also they
may interfere with miRNA induced translation inhibition, thus
acting as competing endogenous RNAs (ceRNAs), or “sponge
RNAs” (22). Such lncRNA-miRNA associations allow for a fine
tuning of gene expression regulation. Therefore, dysregulation of
the lncRNA-miRNA balance could contribute to the onset of
KSHV pathogenesis.
To identify relevant pairs of lncRNA-miRNA in our
model, we used DIANA-LncBase v3 (18). For each of the four
lncRNAs we searched for their highly confident experimentally
supported viral and host miRNA targets, derived from high-
throughput methodologies, which were in turn DE in the
corresponding comparison.
Within the ten most abundant KSHV miRNAs, we found
that five of them have been associated with the human
lncRNAs MALAT1 and NEAT1. When analyzing the targets
(downregulated in KSHV + tumors) of these five miRNAs, we
observed that they share most of the genes obtained with the ten
miRNAs, which is therefore reflected in the same enriched
pathways (Figure 6C and Supplementary Table 7).A B
C
FIGURE 6 | KSHV miRNAs expression analysis in KSHV (+) tumors. (A) Bar plot of KSHV miRNAs relative abundance by showing counts in KSHV (+) tumors.
Underlined are shown the top ten most frequent miRNAs (B) Pathway analysis showing host downregulated target genes of the ten KSHV miRNAs most abundant
in KSHV (+) tumors. (C) Network relationship among lncRNAs, KSHV microRNAs, mRNAs and their enriched pathways.June 2021 | Volume 11 | Article 687629
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the lncRNA-host miRNAs associations. For the in vitro to in vivo
transition dependent of KSHV, 31 miRNAs accomplished the
criteria, of which 23 were upregulated and 8 were downregulated
in KSHV (+) tumors (Figure 7 and Supplementary Table 7).
The highest contribution was made byMalat1 (29 miRNAs) and
Neat1 (21 miRNAs), followed byMeg3 (11 miRNAs) and H19 (8
miRNAs). Among the downregulated miRNAs highlights the
members of the miR17-92 family: miR-17-5p, miR-19a-3p, miR-
20a-5p, and miR-92a-3p. Their respective targets are represented
by genes such as Egfr, Foxo1, Pdgfra, Rb1, Igf1, Map3k1, etc. all
upregulated in KSHV (+) tumors (Figure 7). Other relevant
downregulated miRNAs were miR-128-3p and miR-155-5p,
which target multiple common genes. On the other hand, up-
modulated miRNAs were linked mostly to Malat1 and Neat1.
Remarkably, among them are miR27-b-3p, miR-140-3p, miR-
142-3p, and miR-142-5p, whose gene precursors were also found
up-modulated in KSHV (+) tumors (Figure 2B). As can be seen
in Figure 7, the functional analysis that arose from the lncRNA-
miRNA-mRNA triad shows that the pathways are arranged in an
unsupervised way in three main clusters. The MAPK signaling
together with Pathways in cancer would make up the 1st group,
over-represented by the upregulated target genes contributed
mainly by miR-671-5p, miR-128a-3p, miR-155-5p, and let 7e-5p,
as well as the miRNAs of the miR17-92 cluster. A second group is
integrated by processes related to Viral infection (HPV
infection), Matrix organization and Angiogenesis, represented
by genes contributed by the miRNAs of the miR17-92 cluster,Frontiers in Oncology | www.frontiersin.org 10let-7d-5p and miR-124-3p, along with others (Figure 7). A third
group would be made up of the pathways HIV life cycle and p53
signaling, over-represented by negatively regulated genes, targets
of the miRNAs miR-27b-3p, miR-101a-3p, miR-140-3p, and
miR-142, among others (Figure 7).
For the comparison KSHV (−) tumors versus KSHV (+)
tumors, we obtained a network of the four lncRNAs targeting
26 miRNAs all upregulated in KSHV (+) tumors with their
corresponding downregulated target genes (Figure 8 and
Supplementary Table 7). It is evident a shift in the expression
of specific miRNAs, such as let-7e-5p, let-7d-5p, miR-123-3p, and
miR-31-5p, compared to that observed in the KSHV-dependent
transition. Other relevant miRNAs that appear are miR-26b-5p,
miR-181 (with its variants a, b and c), miR-378-3p, and miR-381-
3p. Here again, the presence of miR-140-3p and miR-378-3p
correlates with their respective immature precursors that had been
identified previously as upregulated along with the lncRNAs
(Figure 3B). By analyzing the mRNA targets of the miRNA
signature, previously identified as downregulated in KSHV (+)
tumors, we obtained a relatively small group of genes that function
in two major related processes: the regulation of cell cycle control
(G1 to S cycle control, p53 activity regulation, MicroRNA regulation
of DDR) and the transcription machinery, with the pre-mRNA
splicing machinery (Spliceosome) and the E2F transcription factor
network (Figure 8). Remarkably, this functional pattern resembles
that observed with the KSHV miRNAs (Figure 6).
Collectively, our analysis revealed a functional network of
lncRNA-miRNA-mRNA in a KSHV animal model.FIGURE 7 | Schematic representation of the experimentally supported triad lncRNA-miRNA-mRNA and the pathways in which the later are involved for the KSHV-
dependent in vitro to in vivo transition. The expression status in KSHV (+) tumors is indicated for miRNAs and their respective targets.June 2021 | Volume 11 | Article 687629
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Drug-Associated Genes or Networks
KS remains potentially life threatening for patients with
advanced or ART-resistant disease, where systemic therapy is
indicated and three FDA-approved agents that include liposomal
anthracyclines are available (4, 23, 24). Despite the effectiveness
of these agents, most patients progress within six to seven
months of treatment and require additional therapy (25).
Therefore, there is a need to develop alternative strategies.
Identifying drugs or clinical candidates that synergize with the
current KS frontline therapeutic approaches has immediate
translational potential that would be realized in a clinical trial
if identified drug combinations show sustained efficacy in animal
models. Our animal model allowed us to develop signatures that
can be used to identify druggable gene or networks defining
relevant AIDS-KS therapeutic targets.
For this end we used two approaches: 1) druggable miRNAs-
gene pairs, and 2) the complete signature of the lncRNA-
miRNA-mRNA network for upregulated genes.
Since miRNAs can affect the expression of druggable genes
eventually affecting drug efficacy, we searched for drugs for the
miRNAs-down/genes-up pairs. We employed the Pharmaco-Mir
Database (19), which identifies associations of miRNAs, genes
they regulate, and the drugs dependent on these genes.
Supplementary Table 8 summarizes the list of drugs identified
for each miRNA-gene pair. Among the drugs identified in our
analysis there were some used against targets in experimental
KSHV models or in clinical practice: Abacavir (mir19a-TNF),
Bevacizumab (miR19a-IGF1), Celecoxib (miR17-RB1), Imatinib
(miR17-PDGFRA), Oxaliplatin (miR19a-IGF1), Sirolimus
(miR19a-IGF1; miR20a-MAP3K5), Sunitinib (miR-128-VEGFC;
miR17-PDGFRA; miR-19a-TNF; miR-20a-PDGFRA), and
Thalidomide (miR19a-TNF) (Table 1, upper half of the table).Frontiers in Oncology | www.frontiersin.org 11As a second approach, we used the signature of the lncRNA-
miRNA-mRNA network from Figure 7 to search for drugs for the
upregulated genes in the drug gene interaction database dgidb
(20). We found, among others, chemotherapeutics agents such as
Cisplatin (targeting SMARCA4, MAP3K1, RB1, EGFR, RRM1,
and BAX) and Bortezomib (targeting PSMD1, RB1, NOTCH1,
PSMA1, and BAX) and HDAC inhibitors, such as Vorinostat
(targeting NPM1 and RB1) (Table 1, bottom half of the table).
Moreover, we found kinase inhibitors such as Palbociclib
(SMARCA4, RB1, RPS6KA3, and CCNE1), Midostaurin
(PDGFRA), and ENMD-2076 (PDGFRA). Finally, Daunorubicin
(APP) that is currently used to treat Kaposi’s sarcoma (26).
Importantly, some of the aforementioned drugs (abacavir,
doxorubicin, bevacizumab, bortezomib, imatinib, sirolimus, and
thalidamide) have been evaluated alone or in combination with
other drugs in different KS clinical trials. The description of such
studies is found in Supplementary Table 8. The fact that our
analyses pointed to drugs that target KS oncogenic pathways
identified in the laboratory or drugs that are currently in use of
being tested in AIDS-KS, reinforces the possibility of involvement
of the KSHV regulated ncRNA network in viral sarcomagenesis.DISCUSSION
Virus-host interactions trigger a set of mechanisms that
eventually affect the expression of host genes involved in the
regulation of the viral replicative cycle as well as the pathogenesis
of the disease (27). Whereas dysregulation of host protein-coding
genes caused by KSHV infection is well explored, host ncRNAs
and KSHV dependency remains poorly characterized. Currently,
miRNAs and lncRNAs are by far two of the most commonly
studied ncRNA biotypes (28, 29).FIGURE 8 | Schematic representation of the experimentally supported triad lncRNA-miRNA-gene and the pathways in which the later are involved for the
comparison KSHV (−) tumor vs KSHV (+) tumor. Pairs lncRNA-miRNA were identified only for the up-modulated miRNAs.June 2021 | Volume 11 | Article 687629
Naipauer et al. Non-Coding RNAs in KSHV TumorigenesisWe have previously developed and characterized a unique
multistep KSHV tumorigenesis model in which cells explanted
from a KSHV (+) tumor that lose the episome can form KSHV
(−) tumors driven by host mutations such as the PDGFRA-
D842V (12, 30). Using NGS on this model, we interrogated the
transcriptional, genetic and epigenetic (CpG island methylation)
landscape upon KSHV tumor formation and upon KSHV-loss
in cells and tumors (13). In such study, we focused on the host
and virus coding genes. Therefore, taking advantage of the
model and the RNA-sequencing technology, we decided—
for this study—to explore the transcriptional consequences of
KSHV tumorigenesis on the ncRNAs setting, with the aim of
identifying a functional interplay between lncRNAs and miRNAs
dependent of KSHV.
Here we identified four relevant lncRNAs upregulated in KSHV
(+) tumors: Malat1, Neat1, H19 andMeg3. Accumulating evidence
has shown that lncRNA exert its functions by regulating the
expression of target genes. As a first approach, using databases
that collects all lncRNA–target relationships confirmed by binding
experimental technologies, we searched for the target genes for the
human homologues of each of the selected lncRNAs. In addition to
having common target genes, pathway analysis showed that the
four lncRNAs also share common related processes, mainly
associated with cancer and viral infections. Interestingly, KSHV
infection andMicroRNAs in cancerwere among the common over-
represented terms.
Next, we interrogated the transcriptome of our model to
identify the 4-lncRNAs common targets into the DEG. The
integrated analysis allowed us to define a reduced group of
host lncRNAs-target genes that significantly would contribute
with KSHV tumorigenesis and related processes. The integration
of the in silico approach of the lncRNAs-EVT and their
associated pathways, with the host transcriptome derived from
our model, reveals a network of gene-pathways closely related
with KSHV oncogenesis: Integrins in angiogenesis, KSHV
infection, signaling by PDGF, HIF1-signaling pathway orFrontiers in Oncology | www.frontiersin.org 12MicroRNAs in cancer were represented by upregulated genes
such as Egfr; Vegfa, Hif1a, Dicer1, Zeb1, Zeb2, Rb1, or Il6.
In addition, one of the distinctive pathways of the in vitro to
in vivo transition dependent of KSHV, provided by the lncRNA
targets, was Extracellular Matrix Organization and Activation of
Matrix Metalloproteinases, overrepresented by the MMPs
Mmp2, Mmp9, Mmp13, and Mmmp14. MMPs are associated
with KS and may contribute to the mechanism of KS tumor
growth. They are usually synthesized by the tumor stromal cells,
including fibroblasts, myofibroblasts, inflammatory cells and
endothelial cells. These components can also integrate a tumor
derived from cells in vitro. Although the mechanism by which
Malat1, Neat1, or H19 regulate the expression of MMPs is not yet
clear, different studies have shown that the silencing or
overexpression of these lncRNAs positively correlate with the
expression of MMPs, such as MMP9 or MMP2 (31–33).
MALAT1 is perhaps the most studied lncRNA and
consequently the one with the most targets. It has been shown
to regulate EGFR expression promoting carcinogenesis (34); it
has been shown to regulate endothelial cell function and vessel
growth (35); it has been defined as a hypoxia-induced lncRNA
(36); it modulates ZEB1 and ZEB2 by sponging miRNAs (37, 38).
Remarkably, MALAT1 expression is induced by the platelet-
derived growth factor BB (PDGF-BB) (39). In a recent study, we
have shown that the KSHV-ligand mediated activation of the
PDGF signaling pathway is critical for KS development (30).
Later, we found that two PDGFs, Pdgfa and Pdgfb, and their
receptor Pdgfra were both hypo-methylated and up-regulated in
KSHV (+) tumors (13). Overall, the evidence clearly shows that
Malat1 is a key regulator of several target genes involved in
KSHV-dependent signaling pathways. It remains to be
determined whether Malat1 is a driver or simply a passenger
of KSHV tumorigenesis.
NEAT1, is closely related toMALAT1 (aka NEAT2), and both
have been shown to bind multiple genomic loci on active genes,
but display distinct binding patterns, suggesting independent butTABLE 1 | Drug-associated to miRNA-gene pairs (upper half of the table) or genes (bottom half of the table) obtained from the lncRNA-miRNA-mRNA network.
Drug miRNA-gene targets Source Drug Tested in Clinical Trials (ID)
ABACAVIR mir19a-TNF Pharmaco-Mir NCT00834457
BEVACIZUMAB miR19a-IGF1 Pharmaco-Mir NCT00055237, NCT01296815, NCT00923936
CELECOXIB miR17-RB1 Pharmaco-Mir –
IMATINIB miR17-PDGFRA Pharmaco-Mir NCT00090987
OXALIPLATIN miR19a-IGF1 Pharmaco-Mir –
SIROLIMUS miR19a-IGF1; miR20a-MAP3K5 Pharmaco-Mir NCT00450320
SUNITINIB miR-128-VEGFC; miR17-PDGFRA; miR-19a-TNF; miR-20a-PDGFRA Pharmaco-Mir –
THALIDOMIDE miR19a-TNF Pharmaco-Mir NCT00049296, NCT00019123
BORTEZOMIB PSMD1, RB1, NOTCH Pharmaco-Mir NCT01016730
Drug gene targets Source Drug Tested in Clinical Trials (ID)
CHEMBL3397300 EGFR DGIdb –
CISPLATIN SMARCA4, RB1, MAP3K1, EGFR DGIdb –
DAUNORUBICIN APP DGIdb NCT00002093, NCT00002985, NCT00427414
ENMD-2076 PDGFR DGIdb –
ISONIAZID TNF DGIdb –
LORLATINIB RB1 DGIdb –
MIDOSTAURIN PDGFRA DGIdb –
PALBOCICLIB SMARCA4, RB1, RPS6KA3 DGIdb –
VORINSTAT RB1 DGIdb –June 2021 | Volume 11 | Article 687629
Naipauer et al. Non-Coding RNAs in KSHV Tumorigenesiscomplementary functions (40). As MALAT1, NEAT1 is retained
in the nucleus where it forms the core structural component of
the paraspeckle sub-organelles. The formation of paraspeckle
increases in response to viral infection or proinflammatory
stimuli (41). Furthermore, Viollet et al. (42) demonstrated that
NEAT1 is upregulated in KSHV infected cells versus non-
infected cells under hypoxic conditions. Our results show that
Neat1 is upregulated in KSHV- cells versus KSHV+ cells and
indeed is upregulated in KHSV (+) tumors, during the in vitro to
in vivo transition. On the other hand, the lncRNA target analysis
showed that Neat1 positively associates with the upregulated
targets Il6, Stat3 and Spp1 in the KSHV (+) tumors. In this
regard, NEAT1 has been shown to strengthen IL-6/STAT3
signaling and promote tumor growth and proliferation through
nuclear trapping of mRNAs and proteins which acts as inhibitors
of the IL-6/STAT3 signaling pathway (43). Previously, it had been
demonstrated that STAT3 is activated by KSHV infection and
correlates with IL6 release in dendritic cells (44). In summary, these
data taking together reveal a host network in which upregulation of
Neat1 would favor the activation of IL6/STAT3 signaling
contributing directly or indirectly to KSHV tumorigenesis.
MEG3 is generally considered as a tumor suppressor lncRNA.
In this study we found a downregulation of Meg3 in KSHV (−)
cells versus KSHV (+) cells. However, a significant increase of the
lncRNA was evidenced in the in vitro to in vivo transition.
Sethuraman et al. (11) showed that KSHV employs its miRNAs
to target MEG3 promoting its downmodulation to potentially
contribute to sarcomagenesis. Therefore, it is possible to
speculate on a downmodulation of Meg3 by the expressed
KSHV miRNAs as an early event in the viral cycle followed by
an upmodulation of Meg3 as a response of the host cell to the
already triggered tumor growth.
KSHV drives latently infected cells towards proliferation by a
variety of mechanisms such as interfering with MEG3 or the p53
pathway through miRNAs or the protein LANA, respectively (11,
45). In this study, we identified that p53 network would be
regulated in a KSHV-dependent manner by the modulation of
key genes targeted by the lncRNAs, such as Casp3, Bax, Mdm2,
Cdkn1a, or Pcna. Interestingly, these genes along with E2f1 are
linked to other related processes such as G1 to S phase regulation
andMicroRNA DDR. KSHV needs to face various cellular defense
mechanisms designed to eradicate the viral infection. One such
response can include DDR response factors, which can promote
an arrest in cell growth (G1-S regulation) and trigger cell death
(p53 network, Apoptosis). Our findings indicate that those
processes would be repressed through the downmodulation of
the mention lncRNA targets in KSHV (−) tumors versus KSHV
(+) tumors, as well as in the KSHV in vitro to in vivo transition.
Remarkably, several studies have shown that viruses including
KSHV have developed suppressive strategies against DDR (9, 46).
In this sense, KSHVmiRNAs are relevant for protecting cells from
DDR (47, 48). In addition, cellular lncRNAs are important gene
regulators of DDR in a process which involve essential players of
miRNA biosynthesis such as DICER1 and DROSHA (22, 48). In
fact, Dicer1 was one of the significantly upregulated target genes
linked to H19 in the comparison KSHV (−) tumors versus KSHVFrontiers in Oncology | www.frontiersin.org 13(+) tumors. In summary, there is a complex network between
KSHV and host ncRNAs that would regulate DDR factors in order
to bypass cell cycle checkpoints.
miRNA analysis revealed a high proportion of upregulated
host miRNAs dependent of KSHV infection. This finding led us
to interrogate the functional processes associated to the miRNAs
targets. Enriched terms were linked to p53 signaling, Spliceosome
and Cell cycle. When evaluating the in vitro to in vivo transition
which involved both up and downregulated miRNAs, processes
such as Integrins in Angiogenesis, Platelet activation, or signaling
by PDGF were associated to the upregulated targets, whereas
viral infection (HPV, HIV) or p53 signaling were linked to the
downregulated targets.
Furthermore, we evaluated the relevance of viral lncRNAs
and miRNAs expression in KSHV tumorigenesis. KSHV
encodes at least 16 potential lncRNAs (49). In our analysis,
we were able to annotate 12 lncRNAs of which 7 showed
detectable levels of expression in KSHV (+) cells and tumors.
PAN RNA (polyadenylated nuclear RNA), the most abundant and
characterized KSHV lncRNA linked to KSHV lytic gene expression
(49), is expressed in KSHV (+) tumors (Supplementary Figure 2)
correlating with the in vivo up-regulation of KSHV lytic gene
expression (13). In addition, we identified as-ORF7 and as-K5/6
upregulated in KHSV (+) tumors compared to KSHV (+) cells.
Although their functions are still not reported, our results indicate
that these transcripts would have a potential role in KSHV
tumorigenesis. Regarding miRNAs, we identified a group of ten
relevant members which constituted the most frequent in mouse
KSHV (+) tumors. Among them highlights K12-4-3p, K12-3-5p,
K12-8-3p, previously identified as highly expressed in human KS
lesions (50). Moreover, K12-4-3p, which represented 50% of the
KSHV miRNAs detected in this analysis in mouse KSHV (+)
tumors, was shown to be able to restore the transforming
phenotype of a mutant KSHV containing a deletion of all KSHV
microRNAs (51), indicating its association with cellular
transformation and tumor induction. Similarly, K12-3-5p was
shown to promotes cell migration and invasion of endothelial
cells (52). The functional analysis of their targets—downregulated
in mouse KSHV (+) tumors—showed enrichment in processes
such as Cell cycle, Spliceosome, RNA transport, MicroRNA
Regulation of DDR, and p53 signaling, coinciding with what was
observed with the host miRNAs, which suggests that viral miRNAs
might mimic cellular miRNAs. It is possible that the same targets
are also relevant to the infection of human cells by KSHV (KSHV
miRNA) and to KSHV pathogenesis (host miRNA) (53, 54).
Since the similarity with the one found with respect to the
lncRNA targets, we decided to carry out an integration network
dependent of KSHV between the 4-lncRNAs, the DE miRNAs
(from virus and host) related to those lncRNAs, their validated
targets, and the related processes.
The integration showed a more concise landscape of the
potential relationships of lncRNA-miRNA-mRNA in a KSHV
setting, in which, once more, highlights that the upregulated
genes are involved in processes, such as pathways in cancer and
those previously closely related to KSHV tumorigenesis,
including Angiogenesis, PDGF signaling, MAPK signaling orJune 2021 | Volume 11 | Article 687629
Naipauer et al. Non-Coding RNAs in KSHV TumorigenesisECM organization. Similarly, down-modulated genes linked
preferentially to p53 signaling, Spliceosome, miRNA regulation
of DDR, or RNA transport, among others. In the latter
Proteasome subunit protein PSMD1, nucleoporins NUP50,
NUP153, nucleolar protein NPM1, or exportin 1 XPO1 have
been shown to modulate HIV infection or other viral cycles (55–
58). In addition, in a preprint article it was postulated an
extensive destruction of the nuclear and nucleolar architecture
during lytic reactivation of KSHV, with redistribution or
degradation of proteins such as NPM1 (59). More interestingly
NPM1 (aka NPM) is a critical regulator of KSHV latency via
functional interactions with v-cyclin and LANA. Strikingly,
depletion of NPM in PEL cells has led to viral reactivation,
and production of new infectious virus particles (60). On the
other hand, using a model of oncogenic virus KSHV-driven
cellular transformation of primary cells, Gruffaz et al. (61)
illustrate that XPO1 is a vulnerable target of cancer cells and
reveal a novel mechanism for blocking cancer cell proliferation
by XPO1 inhibition.
Spliceosome has been other of the relevant terms yielded by
our network analysis. In the presence of KSHV, positively
regulated miRNAs linked to a group of down-modulated
targets closely related to the splicing machinery (Snrpb, Snrpb2,
Rbmx, Srsf3, Srsf10). NEAT1 and MALAT1 were the first
lncRNAs to be identified as having a relevant role in mRNA
splicing in both human and mouse cells. The mechanisms
by which both lncRNAs modulate splicing is extensively
reviewed in Romero-Barrios et al. (62). Remarkably, it has been
postulated thatMALAT1modulates the phosphorylation status of
a pool of Serine/arginine-rich (SR) proteins (proteins involved in
splicing), resulting in the mislocalization of speckle components
and changes in alternative splicing of pre-mRNAs, impacting in
other SR-dependent post-transcriptional regulatory mechanisms,
including RNA export, NMD and translation (63). In addition,
cells depleted forMALAT1 show an increased cytoplasmic pool of
poly(A)+ RNA, suggesting that MALAT1 contribute with the
retention of nuclear mRNAs. Before RNAs can interact with
nuclear export machinery, they must undergo processes that
regulate the number of transcripts that is exported to the
cytoplasm or nuclear decay pathways. KSHV manipulation of
nuclear RNA regulation is one of the strategies acquired by the
virus to influence the host RNAs during viral infection (8). In fact,
it was very recently demonstrated that NMD pathway targets
KSHV RNAs to restrict the virus (10). In summary, our network
reveals another intricate relationship between lncRNA-miRNA-
targets that can function in modulating spliceosome pathway and
RNA transport during virus-host interaction.
Other relevant miRNAs that emerged from our network were
members of the cluster 17-92 and the let-7 family whose multiple
targets regulate different pathways associated with cancer.
Moreover, miR 140-3p or miR378b also stand out, of which,
like miR143-3p, their precursors were found upregulated in
KSHV (+) tumors.
It has been demonstrated that miR140 in the nucleus can
interact with NEAT1, leading to the increased NEAT1 expressionFrontiers in Oncology | www.frontiersin.org 14(64). Remarkably, there is another interesting link with NEAT1,
which is p53 signaling, a frequent pathway represented in our
networks. It has been shown that silencing Neat1 in mice
prevents paraspeckle formation, which sensitizes preneoplastic
cells to DDR activating cell death and impairing skin
tumorigenesis (65). Moreover, activation of p53 stimulates the
formation of NEAT1 paraspeckles, establishing a direct
functional link between p53 and paraspeckle biology (65). P53
regulates NEAT1 expression to stimulate paraspeckle formation
and NEAT1 paraspeckles, in turn, dampen replication-associated
DNA damage and p53 activation in a negative regulatory
feedback (65). These data indicate that upregulation of Neat1
in KSHV (+) tumors could attenuate p53 signaling network, and
infected cells may benefit from this situation evading the p53
checkpoint in response to DNA damage.
As mentioned before, we have used this same mECK36 tumor
model to analyze the consequences of KSHV loss by comparing
the mutational and methylation landscape of KSHV (+) and
KSHV (−) tumors. We found that KSHV loss led to irreversible
oncogenic alterations including oncogenic mutations and
irreversible epigenetic alterations that were essential in driving
oncogenesis in the absence of KSHV (13). In contrast to
these irreversible effects of KSHV tumorigenesis, the ncRNA
network we describe in the present study display a high
degree of plasticity and reversibility upon KSHV loss further
supporting the idea that these oncogenic networks are driving
tumorigenesis and are more strictly dependent on the presence
of KSHV.
Along the study, we integrate mice genes and their
homologues in humans to understand the ncRNA biology in
KSHV tumorigenesis and to develop signatures that can be used
to identify druggable gene or networks defining relevant AIDS-
KS therapeutic targets.
Interestingly, we identified drugs usually used against targets
in experimental KSHV models or in clinical trials: Abacavir,
Bevacizumab, Bortezomib, Celecoxib, Doxorubicin, Imatinib,
Oxaliplatin, Sirolimus, Sunitinib, Thalidomide and Vorinostat.
Interestingly, we have previously shown a combinatory effect
between Bortezomib and Vorinostat for the treatment for
primary effusion lymphoma (66). The fact that our analyses
pointed to drugs that target KS oncogenic pathways identified in
the laboratory or drugs that are currently in use of being tested in
AIDS-KS further validate the bioinformatic analysis in our
KSHV mouse tumorigenic model and reinforces the idea of the
involvement of the KSHV regulated ncRNA network in
viral sarcomagenesis.
In summary, in the present study the integration of the
transcriptional analysis of ncRNAs in a KSHV model in cells
and mouse tumors, with an exhaustive computational analysis of
their experimentally supported targets, has allowed us to dissect a
complex network that defines the main pathways involved in
KSHV pathogenesis and host response. Understanding the
relationships between these different RNA species will allow a
better understanding of the biology of KSHV and can aid in the
identification of relevant AIDS-KS druggable targets.June 2021 | Volume 11 | Article 687629
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